Grace Science Foundation
- Assets
- $3.2m
- Revenue
- $1.2m
- Investments
- $0.0
- Employees
- 0
- Location
- Menlo Park, CA
- Founding
- 07/2014
- Data as of
- 12/2022
- EIN
- 46-5727883
Organization Overview
Grace Science Foundation is located in Menlo Park, CA. The organization was established in 2014. According to its NTEE Classification (H99) the organization is classified as: Medical Research N.E.C., under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Grace Science Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Grace Science Foundation generated $1.2m in total revenue. This organization has experienced exceptional growth, as over the past 7 years, it has increased revenue by an average of 10.9% each year . All expenses for the organization totaled $1.2m during the year ending 12/2022. While expenses have increased by 4.9% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2016, Grace Science Foundation has awarded 66 individual grants totaling $5,986,774. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
SEE PART III LINE 1
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE CHARLES RIVER LABORATORIES TEAM HAS IMPORTED AND IS MAINTAINING A COLONY OF NGLY1 KNOCKOUT RATS FOR USE IN EVALUATING THERAPIES TO TREAT NGLY1 DEFICIENCY. THIS KNOCKOUT MODEL HAS BEEN A KEY FOUNDATION TO TEST ADENO-ASSOCIATED VIRUS (AAV)-MEDIATED GENE DELIVERY FOR RESCUE OF DISEASE-ASSOCIATED PHENOTYPES AND HAS SUPPORTED AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR AN NGLY1 DEFICIENCY GENE THERAPY CLINICAL STUDY. TEAM HAS ALSO CONDUCTED A STUDY TO MONITOR CLINICAL PHENOTYPES AND COLLECT BIOLOGICAL SAMPLES IN HOMOZYGOUS MUTANT AND HETEROZYGOUS (CARRIER) NGLY1 KNOCKOUT RATS ACROSS THE LIFESPAN FROM BIRTH TO EIGHTEEN MONTHS OF AGE.
THE SCRIPPS RESEARCH INSTITUTE (BOLLONG LAB) TEAM IS TESTING THE ABILITY OF SMALL MOLECULE MODULATORS OF THE TRANSCRIPTIONAL REGULATORS NRF1 (NFE2L1) AND NRF2 (NFE2L2) FOR THE RESCUE OF PHENOTYPIC CHANGES ASSOCIATED WITH NGLY1 DEFICIENCY. THE TEAM HAS IDENTIFIED NRF1 MODULATING COMPOUNDS THAT PROTECT NGLY1 KNOCKOUT CELLS FROM PROTEASOMAL STRESS AND HAS BEEN CHARACTERIZING THEIR ACTIVITY. IN ADDITION, A POTENT AND SELECTIVE BRAIN PENETRANT NRF2 MODULATING COMPOUND HAS BEEN IDENTIFIED AND IS BEING CHARACTERIZED AND FORMULATED FOR IN VIVO TESTING. THESE COMPOUNDS ESTABLISH A PROOF OF CONCEPT FOR NGLY1 DEFICIENCY THERAPY DEVELOPMENT BASED ON NRF1/2 MODULATION.
THE T. DAVID GLADSTONE INSTITUTE (FINBEINER LAB) TEAM HAS IMPORTED AND IS ANALYZING CELLULAR PHENOTYPES IN A NEURONAL MODEL OF NGLY1 DEFICIENCY TO DEFINE DISEASE MECHANISMS FOR THE DESIGN AND TESTING OF CANDIDATE THERAPIES. THE TEAM HAS BEEN USING ROBOTIC MICROSCOPY TO INVESTIGATE PHENOTYPIC DIFFERENCES IN AN NGLY1 MUTANT HUMAN NEURAL CELL LINE FOLLOWING DIFFERENTIATION FROM NEURAL PRECURSOR CELLS TO MATURE NEURONS. THE TEAM IS USING GENETICALLY ENCODED BIOSENSORS TO MONITOR CELL VIABILITY, MITOCHONDRIAL SHAPE AND DYNAMICS, PROTEASOMAL ACTIVITY, AUTOPHAGY FLUX, PROTEIN AGGREGATION AND NRF1-DEPENDENT TRANSCRIPTIONAL ACTIVITY. THE GOAL IS TO IDENTIFY CELLULAR CHANGES THAT CAN BE USED TO ASSESS OR SCREEN FOR CANDIDATE DRUGS THAT CAN CORRECT CELLULAR CHANGES CAUSED BY NGLY1 DEFICIENCY.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Matthew Wilsey President | OfficerTrustee | 0 | $0 |
Egon Durban Chief Financial Officer | OfficerTrustee | 0 | $0 |
Ken Drazan Secretary | OfficerTrustee | 0 | $0 |
Pete Briger Director | Trustee | 0 | $0 |
Chelsea Clinton Director | Trustee | 0 | $0 |
J Taylor Crandall Director | Trustee | 0 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $1,206,450 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,206,450 |
| Total Program Service Revenue | $0 |
| Investment income | $29,778 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $1,236,228 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $967,948 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $11,298 |
| Fees for services: Accounting | $12,600 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $139,219 |
| Advertising and promotion | $8,041 |
| Office expenses | $2,395 |
| Information technology | $1,597 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $61,828 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $791 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $970 |
| All other expenses | $0 |
| Total functional expenses | $1,218,482 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $186,218 |
| Savings and temporary cash investments | $2,996,735 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $638 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $3,183,591 |
| Accounts payable and accrued expenses | $51,224 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $51,224 |
| Net assets without donor restrictions | $0 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $3,183,591 |
Grants Awarded
Over the last fiscal year, Grace Science Foundation has awarded $961,221 in support to 14 organizations.
| Grant Recipient | Amount |
|---|---|
CHARLES RIVER LABORATORIES PURPOSE: NGLY1 | $298,348 |
CALIBR PURPOSE: NGLY1 (BOLLONG LAB) | $133,374 |
THE T DAVID GLADSTONE INSTITUTE PURPOSE: NGLY1 (FINKBEINER LAB) | $132,178 |
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTE PURPOSE: NGLY1 (YAN LAB) | $114,390 |
NEW YORK STEM CELL FOUNDATION INC PURPOSE: NGLY1 | $55,000 |
BOSTON CHILDREN'S HOSPITAL PURPOSE: NGLY1 (YU LAB) | $49,110 |